key: cord-0689963-894gkrsk authors: Zhang, Rui; Hristovski, Dimitar; Schutte, Dalton; Kastrin, Andrej; Fiszman, Marcelo; Kilicoglu, Halil title: Drug Repurposing for COVID-19 via Knowledge Graph Completion date: 2021-02-08 journal: J Biomed Inform DOI: 10.1016/j.jbi.2021.103696 sha: ce0796dbcfe142ad84fe9741af76a49a0dd9851a doc_id: 689963 cord_uid: 894gkrsk Objective To discover candidate drugs to repurpose for COVID-19 using literature-derived knowledge and knowledge graph completion methods. Methods We propose a novel, integrative, and neural network-based literature-based discovery (LBD) approach to identify drug candidates from PubMed and other COVID-19-focused research literature. Our approach relies on semantic triples extracted using SemRep (via SemMedDB). We identified an informative and accurate subset of semantic triples using filtering rules and an accuracy classifier developed on a BERT variant. We used this subset to construct a knowledge graph, and applied five state-of-the-art, neural knowledge graph completion algorithms (TransE, RotatE, DistMult, ComplEx, and STELP) to predict drug repurposing candidates. The models were trained and assessed using a time slicing approach and the predicted drugs were compared with a list of drugs reported in the literature and evaluated in clinical trials. These models were complemented by a discovery pattern-based approach. Results Accuracy classifier based on PubMedBERT achieved the best performance (F1 = 0.854) in classifying semantic predications. Among five knowledge graph completion models, TransE outperformed others (MR = 0.923, Hits@1 = 0.417). Some known drugs linked to COVID-19 in the literature were identified, as well as others that have not yet been studied. Discovery patterns enabled identification of additional candidate drugs and generation of plausible hypotheses regarding the links between the candidate drugs and COVID-19. Among them, five highly ranked and novel drugs (paclitaxel, SB 203580, alpha 2-antiplasmin, metoclopramide, and oxymatrine) and the mechanistic explanations for their potential use are further discussed. Conclusion We showed that a LBD approach can be feasible not only for discovering drug candidates for COVID-19, but also for generating mechanistic explanations. Our approach can be generalized to other diseases as well as to other clinical questions. Source code and data are available at https://github.com/kilicogluh/lbd-covid. graph completion models, TransE outperformed others (MR = 0.923, Hits@1 Coronavirus disease 2019 , caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly 2019-nCoV), first emerged in China in late 2019, and was declared a global pandemic by the World Health Organization (WHO) on March 11, 2020. Since then, 5 COVID-19 has disrupted human life across the globe, with enormous human, economic, and societal costs. At the time of writing, it shows no sign of abating [1, 2] , although the final months of 2020 have brought some good news. First, on October 22, 2020, after the initial submission of this manuscript, the Food and Drug Administration (FDA) approved remdesivir for the treatment of COVID-10 19 requiring hospitalization [3] . Then, on November 9, 2020, Pfizer/BioNTech announced the effectiveness of their coronavirus vaccine BNT162b2 and over a month later after the release of additional data, FDA granted it emergency use authorization [4] . A second vaccine, by Moderna, has also been authorized for emergency use on December 18, 2020 [5] . Rapid development of effective vaccines for COVID-19 was by no means guaranteed, however. Moreover, de novo development and approval of an effective antiviral therapy remains a risky, costly, and time-consuming process. In the absence of an effective vaccine or other therapies, there have been significant efforts in repurposing drugs approved for other diseases for COVID-19 treat-20 ment, some of which have been tested in clinical trials (e.g., dexamethasone [6] , hydroxychloroquine and lopinavir/ritonavir [7] ) and one ultimately approved by FDA for treatment of patients hospitalized with COVID-19 (remdesivir [3, 8] ). Computational approaches to drug repurposing have also garnered much attention to accelerate discovery of therapies for COVID-19 [9, 10] . Common com-25 putational drug repurposing methods include drug signature matching, molecular docking, genome-wide association studies, and network analysis [11] . These data-driven approaches involve systematic analysis of various types of biological and clinical data (e.g., gene expression, chemical structure, genome and protein sequences, and electronic health records) to generate hypotheses regarding 30 repurposed use of approved or investigational drugs [11] . The potential of recent advances in artificial intelligence (AI) and machine learning for COVID-19 drug repurposing has also been highlighted [12] and several studies using these techniques have reported promising results [13] [14] [15] [16] . In particular, approaches leveraging network medicine [17] principles and biological knowledge graphs 35 have been emphasized [12] . Most of the computational approaches to drug repurposing have focused on biological data, such as gene expression, protein-protein and drug-target interactions, and used SARS-CoV-2-related data. However, COVID-19-specific data is meaningful in the context of the larger body of diverse knowledge underpinning 40 medicine and life sciences, a primary source of which is the biomedical literature. While some COVID-19 drug repurposing studies incorporated literature-based knowledge [13, 16] , their focus has remained largely COVID-19-specific. We argue that efficiently and safely repurposing drugs to treat COVID-19 requires more effective integration of literature-based knowledge with biological data 45 collected via high-throughput methods. In this paper, we propose a novel literature-based discovery [18, 19] approach for COVID-19 drug repurposing. Similar to related work [16] , we cast drug repurposing as a task of knowledge graph completion (or link prediction). We use a large, literature-derived biomedical knowledge graph constructed from 50 SemMedDB [20] as well as COVID-19 research literature [21] , as our data source. We use several state-of-the-art, neural network-based algorithms [22] [23] [24] [25] [26] for the task, and also complement these approaches with an approach based on discovery patterns [27] . Furthermore, we highlight the role of discovery patterns in search of mechanistic explanations for candidate drugs. Unlike most approaches 55 that focus on COVID-19-specific knowledge [13, 16] , we consider a larger body of biomedical knowledge, as captured in the PubMed bibliographic database as well as in the COVID-19 research literature. Our results show that our approach can identify known drugs that have been used for COVID-19 and discover other novel drugs that can potentially be repurposed for COVID-19. 60 Significant computational work has already been done to prioritize FDAapproved drugs for repurposing to treat COVID-19 [9, 10] . For the most part, these studies can be categorized as molecular docking-based drug screening stud- 65 ies and network-based studies, the majority of them belonging to the former category. In molecular docking studies, small molecules in compound libraries are screened for effectiveness against the host proteins in the SARS-CoV-2 host interactome. Many studies of this kind have been reported, and some of the proposed drugs such as ritonavir, ribavirin, remdesivir, and oseltamivir have 70 been used in practice and many are being evaluated in clinical trials [28] [29] [30] [31] [32] [33] [34] [35] . While not as common as docking studies, network-based approaches to drug repurposing have also been explored. In one early study, a virus-related knowledge graph which consists of drug-target and protein-protein interactions and similarity networks from publicly available databases (e.g., DrugBank [36] , 75 ChEMBL [37] , BioGRID [38] ) was constructed and network-based machine learning and statistical analysis were used to predict an initial list of COVID-19 drug candidates. This list was narrowed down based on text mining from the literature and gene expression profiles from COVID-19 patients, and a poly-ADP-ribose polymerase 1 (PARP1) inhibitor CVL218, was proposed for ther- 80 apeutic use against COVID-19 [13] . Cava et al. [39] used gene expression profiles from public datasets to construct a protein-protein interaction network in conjunction with pathway enrichment analysis to identify 36 potential drugs, including nimesulide, thiabendazole, and fluticasone propionate. In another study, network proximity analyses of drug targets and HCoV-host in- 85 teractions in the human interactome were used to prioritize 16 potential repurposed drugs, including melatonin, mercaptopurine, and sirolimus, which were validated by enrichment analyses of drug-gene signatures and transcriptome data in human cell lines [14] . Potentially useful drug combinations (e.g., melatonin plus mercaptopurine) were also suggested. A follow-up study combined 90 network medicine approaches based on human interactome with clinical patient data from a COVID-19 registry to show that melatonin was associated with reduced likelihood of a positive SARS-CoV-2 laboratory test [15] . The approach was further extended to explore deep learning [16] . A comprehensive knowledge graph of drugs, diseases, and proteins/genes (named CoV-KGE) 95 was constructed by combining molecular interaction information from the literature with knowledge from DrugBank. A knowledge graph embedding model, named RotatE [23] was used to represent the entities and the relationships in the knowledge-based in low-dimensional vector space. Using the ongoing COVID-19 trial data as a validation set, 41 high-confidence repurposed drug candidates 100 (including dexamethasone, indomethacin, niclosamine, and toremifene) were identified, and further validated via an enrichment analysis of gene expression and proteomics data in SARS-CoV-2-infected human cells. Another study used node2vec graph embeddings and variational graph autoencoders for the same purpose [40] . Gysi et al. [41] evaluated three algorithms (graph neural network, 105 network proximity, and network diffusion) on a network of drug protein targets and disease-associated proteins for COVID-19 drug repurposing. While they obtained low correlations across the three algorithms, an ensembling approach that combined the predictions of all algorithms was shown to outperform the individual methods, ranking ritonavir, chloroquine, and dexamethasone among 110 the most promising candidates. Some limited literature knowledge relevant to COVID-19 has been incorporated to network-based approaches; however, their focus remains largely on structured molecular interaction information encoded in databases. 115 Literature-based discovery (LBD) [18, 19] is a method of automatic hypothesis generation pioneered by Swanson [42] . Based on the concept of "undiscovered public knowledge", LBD seeks to uncover valuable hidden connections between disparate research literatures, and has been proposed as a potential solution for the problem of "research silos" (the view that scientific research areas are 120 largely isolated from one another). The primary LBD paradigm is the so-called ABC model. In the open discovery form of this model, a relationship between two concepts A and B is known in one research area and another relationship between concepts B and C is known in another, and a potential relationship between concepts A and C is proposed. Conversely, in closed discovery, re-125 lationship AC is known, and a concept B is proposed as an explanation for the relationship AC. Extensions to ABC model have also been proposed, such as discovery browsing model that aims to elucidate more complex relationship paths between biomedical concepts [43, 44] Knowledge graphs are represented as a collection of head entity-relation-145 tail entity triples (h, r, t), where entities correspond to nodes and relations to edges between them. Knowledge graph completion is the task of predicting unseen relations between two existing entities or to predict the tail entity given the head entity and the relation (or head entity given the tail entity and the relation). Recent approaches to knowledge graph completion rely on knowl-150 edge graph embedding methods [59], which learn a mapping from nodes and edges to continuous vector space that preserve the proximity structure of the knowledge graph and are amenable to application of machine learning methods. Such methods include translational models, which use distance-based scoring functions (e.g., TransE [22] , TransH [60] , RotatE [23] ), and semantic matching 155 models, which use similarity-based scoring functions (e.g., RESCAL [61] , Dist-Mult [24] , ComplEx [25], and HolE [62] ). Graph convolutional networks [63, 64] as well as methods that use context-based encoding approach (KG-BERT [65] , STELP [26] ) have also been recently proposed. Knowledge graph embedding techniques based on a network of drug, disease, and gene/protein entities have been used to support drug repurposing for rare diseases [66] . Graph convolutional networks were used to model drug side effects resulting from drug-drug interactions [67] . A multimodal graph of protein-protein, drug-protein target, and drug-drug interactions was constructed from publicly available datasets. Sang et al. [68] constructed low-dimensional knowledge graph embeddings from 165 SemMedDB relations and trained a Long Short-Term Memory (LSTM) model using known drug therapies from Therapeutic Target Database [69] to propose potential drugs using the trained model. In this section, we first describe our data sources and the preprocessing 170 steps that were taken to construct a literature knowledge graph from these data sources. Next, we discuss the knowledge graph completion methods that we used to predict candidate drugs for COVID-19 as well as the discovery patterns used for providing mechanistic explanations. Lastly, we detail various evaluation schemes that we used to validate our predictions. A workflow diagram 175 illustrating our approach is provided in Fig. 1 . Our source code and data are publicly available at https://github.com/kilicogluh/lbd-covid. We constructed our biomedical knowledge graph primarily from SemMedDB [20] , a repository of semantic relations automatically extracted from biomedi- [21] . Not all of these articles are included in PubMed. To ensure that our knowledge graph provides adequate coverage of COVID-19 knowledge, we included CORD-19 articles not included in PubMed, as well, and used SemRep to extract relations from titles and abstracts of these articles. We In this work, we focused on a subset of semantic relations derived from the combination of PubMed and CORD-19 datasets, predicted to be accurate and 215 informative for drug repurposing. First, we eliminated relations involving generic biomedical concepts (i.e., relations in which both subject and object were present in the GENERIC CONCEPT table of SemMedDB such as Pharmaceutical Preparations) and relations with identical subject and object arguments. Next, we excluded a subset of 220 predicate types that were not expected to be useful for drug repurposing, such as part of and process of. The predicate types we used are affects, associated with, augments, causes, coexists with, complicates, disrupts, inhibits, interacts with, manifestation of, predisposes, prevents, produces, stimulates, and treats. Lastly, we also excluded the re- In the second step, we eliminated (i) high-degree concepts using network degree centrality and (ii) uninformative semantic relations using log-likelihood ratio. The adjacency matrix A of a knowledge graph (i.e., directed network with multiedges) with n nodes (i.e., concepts) has entries A ij = 1 if there is a relation from concept i to concept j. The in-and out-degrees of concept i can then be expressed as [80] : To filter out uninformative links, we assigned each semantic relation a G 2 score indicating how strongly the terms within a triple are associated with each other [81] . A high G 2 score means that the observed and expected frequencies are significantly different, indicating that the triple is less likely to occur by chance. For computational purposes, we created two three-dimensional contingency tables with indices i, j, and k. The first table (OT) holds observed frequencies of a triple from the knowledge graph and the second table (ET) contains the expected values assuming independence of terms in each triple. G 2 was then calculated using the equation where n ijk is the cell i, j, k in OT, m ijk is the cell i, j, k in ET, and T = n ijk . Next, we normalized all three measures (G 2 , k in i , and k out i ) to the range [0, 1] and summed them up into a final score. The lower the score, the more specific and informative the relation is. For example, the relation Operative Surgical Procedures-treats-Woman which has a high score is more general than relation interleukin-6-affects-Autoimmune Diseases. We also kept 235 all relations with biomedical concepts that refer to COVID-19 terms in the UMLS 2 : The precision of semantic predications generated by SemRep vary by domain 250 (e.g., clinical relationships are more precise than molecular interactions). To improve the precision of the relations used for drug repurposing, we extended the SemRep accuracy classifiers previously proposed [82, 83] . We fine-tuned a collection of Transformer-based pretrained language models to classify semantic predications as correct vs. incorrect. We used the following models: vanilla 255 BERT (base size, cased and uncased) [84] , BioBERT [85] , BioClinicalBERT [86], BlueBERT [87] , and PubMedBERT [88] . To extend the coverage of our existing classifiers, we used 6492 predications annotated as correct vs. incorrect with respect to their source sentences. We leveraged 6000 annotations from a previous study [83] (Cohen's κ = 0.80) and 260 annotated 492 new predications. Annotation guidelines generated in the previous study was used. Two of the authors (HK and MF) and two health informatics graduate students annotated predications containing predicates of interest absent in the prior study (Fleiss' κ = 0.41, indicating moderate agreement). Fleiss' κ was used in this case, as more than two annotators were involved in 265 annotation [89] . The resulting annotated set was split into 80/10/10 training/validation/test sets. Hyperparameters were determined empirically and the learning rate was set to 1 × 10 −5 , the batch size was 16, the maximum number of epochs was set to 10 but early stopping was employed. Optimization was done using the 270 Adam optimizer [90] with decoupled weight decay regularization using betas (0.9, 0.999) and decay 0.01. The pooled output from the BERT model was fed through a linear layer to produce logits that then underwent a softmax transformation to return class probabilities. A single Tesla V100 GPU was used to train the models. We compared the performance of various above-mentioned 275 transformers. The best classifier was then used to filter incorrect semantic predications. This resulted in 1 016 124 relations being kept for the knowledge graph completion methods. Consider a knowledge graph G = (E, R, E), where E refers to a set of entities, 280 R denotes a set of possible relations, and T stands for a set of triples in the form and r ∈ R. In this setting, the knowledge graph completion problem could be represented as a ranking task in which a prediction function ψ(h, r, t) : E × R × 285 E → R which generates higher scores for true triples and lower scores for false triples is learned. We explored three classes of knowledge graph completion methods: TransE [22] and RotatE [23] for translational models, DistMult [24] and ComplEx [25] for semantic matching models, and STELP [26] for context-based encoding. These methods differ in the way that they encode entities and relations in a knowledge graph into a low-dimensional vector space (i.e., knowledge graph embedding). Such distributed vector representations can be used for downstream reasoning and machine learning tasks. 295 TransE [22] describes a triplet (h, r, t) as a translation between head entity h and tail entity t through relation r in a continuous vector space, i.e., h + r ≈ t, where h, r, t ∈ R d is the embedding of h, r, and t, respectively. To measure plausibility of relations TransE employs a distance-based score function s(h, r, t) = h + r − t . Either L 1 or L 2 norm can be employed. Figure 2 300 illustrates TransE model with two-dimensional embedding. If (h, r, t) is true, the embedding of the tail entity t (i.e., COVID-19) should be close to the embedding of the head entity h (i.e., Metoclopramide) plus vector that depends on the relationship r (i.e., We choose TransE because of its simplicity and good prediction performance. However, TransE is able to model only one-to-one relations and fails to embed one-to-many, many-to-one, and many-to-many relations. To solve this problem, several other solutions have been proposed including RotatE [23] . RotatE treats 305 each relation in a complex vector space as a rotation from the head entity to the tail entity, i.e., s(h, r, t) = |h • r − t| l1 , where • is a Hadamard product. We selected RotatE as a counterpart to TransE, as TransE reportedly does not perform well on some data sets (e.g., FB15k benchmark data set [22] , commonly used in knowledge graph completion), which require symmetric pattern 310 modeling. DistMult [24] is the simplest approach among semantic matching models. Its scoring function is defined as s(h, r, t) = h, r, t . However, DistMult is limited only to symmetric relations, generating same scores for triples (h, r, t) Semantic Triple Encoder for Link Prediction (STELP) [26] , is a contextbased encoding approach to knowledge graph completion. At its core is a Siamese BERT model that leverages sharing one set of weights across two models to produce encoded, contextual representations of the relations that are then fed to either a multi-layer perceptron (MLP) for classification or a similarity function for contrasting. The STELP architecture uses two learning objectives for training: triple classification and triple contrasting. The final learning objective is a linear combination of the two. During training, STELP takes a single positive relation (h, r, t), and produces five negative relations (h, r, t ) by corrupting the tail. The head context, (h, r), term is sent into one BERT model while each tail, (t) or (t ), are each sent to the other BERT model that shares weights with the other. The classification objective seeks to classify (h, r, t) as 1 and each (h, r, t ) as 0 while the contrastive objective seeks to measure the distance between the contextual embedding of the head and tail portions in a learned semantic space. Formally, the classification loss and constrastive loss functions are as follows: where γ is a scaling factor for the contribution of the contrastive loss. At inference, STELP considers every entity-context combination for a given partial relation, (h, r) to find (t) or (r, t) to find (h), and ranks every pair using This search yielded a set of 1167 clinical trials. We extracted all the interventions used in these studies and mapped the intervention terms to UMLS CUIs using MetaMap (v2016) [92] and filtered the resulting concepts by their semantic groups [93] , keeping only those concepts with the semantic group Chemicals 385 & Drugs. Additionally, we considered the semantic types Therapeutic Procedure and Gene or Genome, which also appeared for some concepts in intervention lists. We removed the duplicates from the resulting concept list and some general concepts (e.g., Therapeutic procedure, Placebo) as well as incorrect mappings. Drug concepts that only differ in their dosage or mode of admin- Time slicing is an evaluation technique often used in LBD and link prediction tasks [18] . The idea is to train models on data prior to a specific date and test them on data after that date and evaluate whether links that formed only after the cutoff date can be predicted from the trained model. In this study, 400 we trained our models on semantic relations extracted from publications dated 03/11/2020 or earlier and tested whether they can predict the drugs that have been proposed for COVID-19 since then or have been evaluated in clinical trials. This date was selected as cutoff, as it is the date on which WHO declared COVID-19 a pandemic. It is also a date by which enough biological knowledge 405 about SARS-CoV-2 had accumulated, although COVID-19 therapies were still in their infancy, making it a suitable cutoff for time slicing experiments. All five knowledge graph completion models were automatically assessed using an evaluation protocol proposed by Bordes et al. [22] . Suppose that X is a set of triples, Θ E be the embeddings of entities E, and Θ R be the embeddings of relations R. In the first, corruption step, we go through a set of triples and for each triple x = (h, r, t) ∈ X replace its head and tail with all other entities in E. Each triple is corrupted exactly 2|E| − 1 times. Formally, the corrupted triple is defined as: where h = h and t = t. We employ the filtered setting protocol not taking into account any corrupted triple that already appears in the knowledge graph. In the second, scoring phase, original and corrupted triples are tested using the constructed classifier ψ. Intuition behind this is that the model will assign a higher score to the original triple and a lower score to the corrupted triple. In the third, evaluation phase, the proposed models are assessed using three measures: mean rank (MR), mean reciprocal rank (MRR), and Hits@k measure. MR is an average rank assigned to the true relation, over all relations in a test set: where rank h i and rank t i denote the rank position: where the indicator function I[P ] is 1 iff P is true, and 0 otherwise. MRR is the average inverse rank for all test triples and is formally computed as: Hits@k measures the percentage of relations in which the true triple appears in the top k ranked triples, where k ∈ {1, 3, 10}; formally: Our aim was to achieve low MR and high MRR and Hits@k. In addition, we also performed a qualitative evaluation. One of the authors (MF, MD with a PhD in medical informatics) used Neo4j browser to assess the plausibility of some of the drugs highly ranked by the knowledge completion models, guided by literature search and review, using closed discovery. We also We report the performance of the semantic relation accuracy classifier as well as the knowledge graph completion methods in this section. We also provide a comparison of the drug lists proposed in previous studies and identified by our methods. The knowledge graph completion results for all employed models are presented in Table 3 . For MR a lower score is considered better, for all others a higher score is considered better. The score for each method is the mean value over all triplets in the testing set. Next, we use t-SNE (t-distributed stochastic neighbor embedding) [95] algorithm to graphically represent embeddings of computed concepts in a twodimensional space (Figure 4 ). t-SNE algorithm enables reduction of high-455 dimensional data into a low-dimensional space such that similar concepts are presented by nearby points. The plot demonstrates relatively good co-localization of selected concepts, especially for Suspected COVID-19 and paclitaxel. with RotatE, as well as hydrocortisone and indomethacin with Zeng et al. [16] . Table 5 lists the overlapping candidate drugs for different methods. Thus far, the following classes of drugs have been used for the management 485 of COVID-19: antivirals, monoclonal antibodies, anti-inflammatory agents, im- The knowledge graph completion models predicted drugs in all these classes, although they did not always rank them highly. For example, TransE pre- vidual drugs and drug classes (with little overlap), whereas STELP predictions were largely limited to very specific drugs and also included natural substances such as bioflavonoid quercetin and riboflavin (vitamin B2). While the quantitative evaluation against clinical trial data suggests TransE as the best-performing 500 model, it is worth noting that this only measures how well a method predicts drugs that are currently being trialed. It is difficult to assess the ultimate clinical effectiveness of the proposed drugs, and it is possible that models that do not perform as well quantitatively yield results that prove more promising (as in the case of RotatE and dexamethasone). Despite these issues, qualitative as-505 sessment of knowledge graph completion models showed that all methods could identify useful repurposing candidates. The results indicate that more complex knowledge graph completion models might not be very efficient in drug repurposing tasks. Due to its relative simplicity, it might be expected that TransE be outperformed by its succes- dence shows that DistMult and ComplEx usually perform well for high-degree entities, but fails with low-degree entities [98] . Because we eliminated highly frequent concepts due to their lack of informativeness, it is possible that this is reflected in lower performance of both models. The context-encoding model, STELP, showed rather poor performance in 520 evaluation. One possibility is that the model was only able to learn high-level groupings for the predicates. This is likely the case as it was observed the model versus affects-COVID-19 etc., it did not learn more granular features that allow it to differentiate between subjects within the context of treats-COVID-19. However, analysis of the t-SNE embedding and the qualitative evaluation show that the model mostly clustered the ground truth drugs into a couple of large 530 clusters. To further compare the drug rankings between TransE and STELP, we performed the Wilcoxon signed-rank test, which shows no correlation between how the two models were ranking novel relations (p = 0.846). Spearman's rank correlation between the novel relation rankings for both models was found to be 535 −0.004, which further supports the results of the Wilcoxon test. Table 6 and Table 7 show that there is very little agreement between TransE and STELP, particularly in the top 1000 rankings for each model. It is worth noting that there were 47 items in common in the top 1000 rankings for both models. ranked triples for the specified model, calculating the absolute difference between the rankings from the two models for each of those triples, and calculating the statistics. For example, the triples that TransE ranked as the top 1000 triples were gathered, the absolute differences of rankings between TransE and STELP for those 1000 triples were calculated, and the statistics were calculated from those differences. The TransE and RotatE are much faster to train than the STELP model (approximately 15 minutes vs. 5 days on our dataset). Due to the size of BERT, which lies at the core of the architecture, STELP is a computationally Using the open discovery pattern approach, we identified five promising drugs that were ranked highly and were not, to our knowledge, discussed in 575 the literature (paclitaxel, SB 203580, alpha 2-antiplasmin, pyrrolidine dithiocarbamate, and butylated hydroxytoluene). The same approach also ranked highly some drugs and substances evaluated in clinical trials (e.g., quercetin, melatonin, vitamin D, estradiol, and simvastatin). We discuss three that have not been proposed for COVID-19 in more detail below (paclitaxel, SB 203580, 580 and alpha 2-antiplasmin). Notably, paclitaxel as well as quercetin, melatonin, vitamin D, estradiol, and simvastatin were predicted by the knowledge graph completion models. Figure 5 shows a network resulting from the aforementioned discovery pattern generated by Neo4j browser. We also used discovery patterns to generate mechanistic explanations for 585 two other drugs ranked highly by TransE and deemed plausible. These drugs are metoclopramide and oxymatrine, which are also discussed in more detail below. Paclitaxel is used to treat several cancer types, including ovarian cancer, state of hypercoagulability by acting as an inhibitor of thromboplastin [101] . The final pattern involves the interaction of paclitaxel with TLR4. Paclitaxel is known to have high affinity for TLR4 receptors. SARS-CoV-2 Spike protein binds with human innate immune receptors, mainly TLR4, increasing secretion of IL-6 and TNF-α and neuroimmune response. This suggests that paclitaxel may dislocate SARS-CoV-2 Spike proteins [102, 103] . 620 We note that paclitaxel, as a chemotherapy drug, is associated with adverse effects, some serious, such as neutropenia, leukopenia, alopecia, arthralgia, myalgia, and peripheral neuropathy [104] . SB 203580 is a specific inhibitor of p38α, which suppresses downstream 625 activation of MAPKAP kinase-2, involved in many cellular processes including stress and inflammatory responses and cell proliferation. The following patterns support the SB 203580 discovery: factor (TNF) production in monocytes, and this resulted in inhibition of septic (infammatory) shock." Alpha 2-antiplasmin is a serine protease inhibitor responsible for inactivating plasmin. Elevated plasmin is a common risk factor for COVID-19 susceptibility, especially in patients with comorbidities such as hypertension, diabetes, and coronary heart disease [106] . The following patterns support the alpha 650 2-antiplasmin discovery: 1. Alpha 2-antiplasmin-inhibits-plasmin-predisposes-COVID-19 2. Alpha 2-antiplasmin-inhibits-fibrinogen-associated with-COVID-19 More specifically, plasmin may cleave a newly inserted furin site in the S pro-655 tein of SARS-CoV-2, which increases its infectivity and virulence in COVID-19. In addition, fibrinogen levels are higher in COVID-19 patients and may contribute to hypercoagulability [106] . By inhibiting plasmin and fibrinogen (first Metoclopramide is, mostly, a dopamine D2 antagonist but acts on many other neurotransmitters and proteins. Using our discovery pattern, we identified two pathways through which metoclopramide may protect against COVID-19. 2. metoclopramide-inhibits-TNF protein, humanassociated with-COVID-19 The first pattern suggests a cholinergic pathway for the protective effect of 680 metoclopramide. The first relation of this pattern is extracted from a study which suggests that metoclopramide activates the sympathetic nervous system by mediating the central cholinergic system in humans [109] . The second piece of the evidence is based on a paper that explains how a cholinergic antiinflammatory pathway acting through acetylcholine receptors can inhibit the 685 production of pro-inflammatory cytokines [110] . Therefore, by activating the cholinergic pathway, metaclopropamide may prevent the inflammatory cytokine storm associated with COVID-19. The second potential link is via tumor necrosis factor-α (TNF-α), a cytokine used by the immune system for cell signaling. The inhibitory effect of metoclo-690 pramide on TNF-α is suggested by a study on anti-inflammatory properties of benzamides, a class of drugs to which metoclopramide belongs ("Our data have shown that metoclopramide . . . gave dose dependent inhibition of TNFα" [111] ). The second piece of the link comes from a paper that studies the role of TNF-α as a key driver of inflammatory macrophage response in severe COVID-19 and 695 proposes anti-cytokine (especially, anti-TNF) treatment for COVID-19 [112]. Oxymatrine is a quinazine alkaloid with organ-and tissue-protective effects, primarily related to its anti-inflammatory, anti-oxidative stress, anti-or proapoptotic, anti-fibrotic, metabolism-regulating, and anti-nociceptive functions 700 [113] . In addition, a variety of signal pathways, cells, and molecules are influenced by oxymatrine. The following patterns support the repurposing of oxymatrine: 1. oxymatrine-inhibits-interleukin-6predisposes-COVID-19 705 2. oxymatrine-inhibits-TNF protein, human-associated with-COVID-19 3. oxymatrine-inhibits-interleukin-1, beta- 6. oxymatrine-inhibits-TLR4 geneassociated with-COVID-19 The first five patterns illustrate the effect of oxymatrine on proinflammatory cytokine and chemokine production induced by SARS-CoV-2. The first piece of 715 the evidence is often an inhibitory relationship, as stated in Huang et al. [114] : "Oxymatrine at 120mg/kg significantly suppressed gene expressions of TLR-4 and NF-κB, decreased levels of TNF-α, interleukin-1beta and interleukin-6". The relationship between cytokine response and COVID-19 is well-established, for example as stated in Chi et al. [115] : "IL-6, IL-7, IL-10, . . . were found to 720 be associated with the severity of COVID-19". Furthermore, the authors of the latter article propose that immunomodulatory treatment to regulate the cytokine responses could be an effective therapeutic strategy for SARS-CoV-2 infection. Oxymatrine could be one such candidate. antagonists (such as oxymatrine) could pave the way for COVID-19 treatment. As error analysis, we manually examined the top 150 predictions by the best-performing model, TransE, for plausibility. 99 of these were deemed im-plausible, as they were drug classes that were considered too general. Examples of such classes include C0003205: Anti-Infective Agents, C0003367: Antilipemic Agents, and C0010858: Cytostatic Agents. As noted above, 735 some members of these classes may indeed be plausible; however, the classes themselves were considered errors. A more systematic approach to exclude drug classes (e.g., by using MeSH concept hierarchy) could help reduce such errors. A more fine-grained evaluation could also consider such cases as partially correct, although this is unlikely to be useful for drug repurposing. The other 18 candidates in the list that were deemed implausible are those that were classified as pharmacologic substances in UMLS, but were not drugs. These include C0279328: hyperbaric oxygen, C1618233: husk and C1443923: Oral rehydration, among others. It may be possible to leverage drug knowledge resources, such as DrugBank, to exclude such concepts and reduce errors. Our approach relies on accuracy of the predications extracted by SemRep. SemRep precision is about 0.70 and its recall around 0.42 [71] . While the accuracy classifier helped us improve the accuracy of the predications used, the remaining errors were still significant, impacting the knowledge graph comple-750 tion task. In addition, despite aggressive filtering, the graph formed by the relations in extended SemMedDB is very large, making it difficult to apply computationally intensive models like STELP. In this study, we examined a sub-graph which, inevitably, results in a loss of information available to knowledge graph 755 completion techniques. While we were still able to apply modeling techniques to a fairly large sub-graph focusing on drug repurposing, there exists a larger, complementary sub-graph that may provide further drug candidates. As noted above, the TransE model benefited from hyperparameter tuning using a grid search method to find an optimal configuration. Similarly, STELP 760 would likely benefit from a similar tuning to find an optimal configuration. For example, a single linear layer was used on the pooled output from the BioBERT model to produce the logits when increasing the representational capacity of the linear layer, by depth or width, might allow for STELP to develop a richer model of the underlying space formed by the BioBERT contextualized embeddings. Our methods were limited to knowledge from the literature. Other types of biological data (e.g., protein-protein interactions, drug-target interactions, gene/protein sequences, pharmacogenomic and pharmacokinetic data) are likely to benefit identification of drug candidates, as shown to some extent by other studies [12] , as well as our prior work [53] . However, the computational re-770 sources needed for training models based on such massive data can be prohibitive. TransE and similar methods seem more promising in that respect. Lastly, with our in silico approach, we can of course only propose drug candidates for repurposing. To evaluate whether these drugs could indeed act as effective treatments for COVID-19, wet lab experiments and clinical studies 775 are needed. However, the fact that we were able to identify drugs known to have some benefit for COVID-19 (e.g., dexamethasone) via purely computational methods that rely only on automatically extracted literature knowledge is encouraging. Moreover, the use of discovery patterns to explain why a particular drug or substance could be beneficial in prioritizing the most promising 780 candidates for such studies. In this study, we proposed an approach that combines literature-based discovery and knowledge graph completion for COVID-19 drug repurposing. Unlike similar efforts that largely focused on COVID-19-specific knowledge, we 785 incorporated knowledge from a wider range of biomedical literature. We used state-of-the-art knowledge graph completion models as well as simple but effective discovery patterns to identify candidate drugs. We also demonstrated the use of these patterns for generating plausible mechanistic explanations, showing the complementary nature of both methods. repurpose drugs for other diseases. It can also be generalized to answer other clinical questions, such as discovering drug-drug interactions or identifying drug adverse effects. As COVID-19 pandemic continues its spread and disruption around the 795 globe, we are reminded how the spread of infectious diseases is increasingly common and future pandemics ever more likely. Innovative computational methods leveraging existing biomedical knowledge and infrastructure could help us plan for, respond to, and mitigate the effects of such global health crises. Drug repurposing is a key piece of this response, and our approach provides an efficient 800 computational method to facilitate this goal. SB 203580-inhibits-interleukin-6 -causes SB 203580-inhibits-TNF protein, human-associated with 203580-inhibits-interleukin-1, beta-associated with-COVID-19 4. SB 203580-inhibits-interleukin-8-predisposes-COVID-19 5. SB 203580-inhibits-NF-kappa B-associated with-COVID-19 6 203580-inhibits-Granulocyte-Macrophage Colony-Stimulating Factor 635 -associated with SB 203580-inhibits-Interleukin-17-associated with SB 203580-inhibits-Macrophage Colony-Stimulating Factorassociated with Similarly to paclixatel, all patterns involving SB 203580 point to a poten-640 tial inhibition of the hyperinflammatory response in COVID-19. According to Gaestel [105], "the role of the protein kinases p38α in inflammation and innate immunity was found when the compound SB 203580 FDA Approves First Treatment for COVID-19 FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine fda-takes-addi tional-action-fight-against-covid-19-issuing-emergency-use 830 -authorization-second-covid Dexamethasone in hospitalized patients with covid-19-preliminary report Ef-835 fect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial Remdesivir for the treatment of Covid-19-preliminary report Current status of COVID-19 therapies and drug repositioning applications COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays Drug repurposing: 850 progress, challenges and recommendations Artificial intelligence in COVID-19 drug repurposing, The Lancet Digital Health A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19 Networkbased drug repurposing for novel coronavirus 2019-ncov/sars-cov-2 A network medicine approach 865 to investigation and population-based validation of disease manifestations and drug repurposing for covid-19 Repurpose open data to discover therapeutics for 870 covid-19 using deep learning Network medicine: a networkbased approach to human disease Literature based discovery: models, methods, 875 and trends Emerging approaches in literature-based discovery: techniques and performance review SemMedDB: a PubMed-scale repository of biomedical semantic predications Proceedings of the 1st Workshop on NLP for COVID-19 at ACL 2020 Trans-890 lating embeddings for modeling multi-relational data RotatE: Knowledge Graph Embedding 895 by Relational Rotation in Complex sSpace Embedding entities and relations for learning and inference in knowledge bases Complex embeddings for simple link prediction Semantic triple encoder for fast open-set link prediction Exploiting semantic relations for literature-based discovery A 910 sars-cov-2 protein interaction map reveals targets for drug repurposing Discovery of sars-cov-2 antiviral drugs through large-scale compound re-915 purposing Analysis of therapeutic targets for sars-cov-2 and discovery of potential drugs by computational methods Anti-hcv, nucleotide inhibitors, repurposing against covid-19 Virtual screening and repurposing of fda approved drugs against covid-19 main protease Using integrated com-925 putational approaches to identify safe and rapid treatment for sars-cov-2 Fast identification of possible drug treatment of coronavirus disease-19 (covid-19) through computational drug repurposing study Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against sars-cov-2 rna dependent rna polymerase (rdrp): A molecular docking study Drugbank: a knowledgebase for drugs, drug 935 actions and drug targets Chembl: a large-scale bioactivity database for drug discovery Biogrid: a general repository for interaction datasets In silico discovery of candidate drugs 945 against covid-19 Predicting potential drug targets and repurposable drugs for covid-19 via a deep generative model for graphs work for identifying drug repurposing opportunities for covid-19 Fish oil, Raynaud's syndrome, and undiscovered public knowledge., Perspectives in biology and medicine Graph-based methods for discovery browsing with semantic predications Semantic MEDLINE for discovery browsing: using semantic predications and the literature-based discovery paradigm to elucidate a mechanism for the obesity paradox An interactive system for finding complementary literatures: a stimulus to scientific discovery Using concepts in literature-based discovery: Simulating swanson's raynaud-fish oil 970 and migraine-magnesium discoveries Using the literature-based discovery paradigm to investigate drug mechanisms Exploring relation types for literature-based discovery Context-driven automatic subgraph creation for literature-based discovery Reflective random indexing and indirect inference: A scalable method for discovery of implicit connections Finding schizophrenia's prozac emergent relational similarity in predication space Embedding of semantic predications Combining semantic relations and dna microarray data for novel hypotheses generation Using literature-based discovery to identify novel therapeutic approaches Predicting high-throughput screening results with scalable literature-based discovery methods semantics to identify potential prostate cancer drugs A new method for prioritizing drug repositioning candidates extracted by 1010 literature-based discovery Literature-based discovery of new candidates for drug repurposing Knowledge graph embedding: A survey of approaches and applications Knowledge graph embedding by translating on hyperplanes A three-way model for collective learning on multi-relational data., in: ICML Holographic embeddings of knowledge graphs Convolutional 2d knowledge graph embeddings Modeling relational data with graph convolutional networks, 1030 in: European Semantic Web Conference Kg-bert: Bert for knowledge graph completion A literaturebased knowledge graph embedding method for identifying drug repurpos-1035 ing opportunities in rare diseases Modeling polypharmacy side effects with graph convolutional networks Gredel: A knowledge graph embedding based method for drug discovery from biomedical literatures Ttd: therapeutic target database The interaction of domain knowledge and linguistic structure in natural language processing: interpreting hypernymic propositions in biomedical text Broad-coverage biomed-1050 ical relation extraction with semrep The Unified Medical Language System The Unified Medical Language System (UMLS): integrating biomedical terminology Augmenting microarray data with literature-based knowledge to enhance gene regulatory network inference Link prediction on the seman-1065 tic medline network Are abstracts enough for hypothesis generation? Investigating the role of interleukin-1 beta and glutamate in inflammatory bowel disease and epilepsy using discovery browsing Keep up with the latest coronavirus research Complex networks: Structure and dynamics Extending the log-likelihood measure to improve colloca-1080 tion identification, Master's thesis Mining biomedical literature to explore interactions between cancer drugs and dietary supplements Evaluating active learning methods for annotating semantic predications Bert: Pre-training of deep 1090 bidirectional transformers for language understanding Biobert: a pre-trained biomedical language representation model for biomedical text mining Proceedings of the 2nd Clinical Natural Language Processing Workshop Transfer learning in biomedical natural language 1100 processing: An evaluation of bert and elmo on ten benchmarking datasets Domain-specific language model pretraining for biomed-1105 ical natural language processing Measuring nominal scale agreement among many raters Adam: A method for stochastic optimization Training knowledge graph embeddings at scale An overview of MetaMap: historical perspective and recent advances Aggregating UMLS semantic types for reducing conceptual complexity Drug repurposing approach to fight COVID-19 Visualizing data using t-SNE Pharmacologic treatments for coronavirus disease 2019 (covid-19): a review Pathophysiology, transmission, diagnosis, and treatment of coronavirus 1130 disease 2019 (COVID-19): a review A capsule network-based embedding model for knowledge graph completion and search personalization How taxol/paclitaxel kills cancer cells The trinity of COVID-19: immunity, inflammation and intervention COVID-19: coagulopathy, risk of thrombo-1140 sis, and the rationale for anticoagulation, Clinical and Applied Thrombosis The role of TLR4 in chemotherapy-driven metastasis Is Tolllike receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? DailyMed: Paclitaxel injection What goes up must come down: molecular basis of MAP-KAP kinase 2/3-dependent regulation of the inflammatory response and its inhibition Elevated plasmin (ogen) as 1155 a common risk factor for COVID-19 susceptibility IgY-turning the page toward passive immunization in COVID-19 infection Purification of human α2-antiplasmin with chicken IgY specific to its carboxy-terminal peptide Effect of metoclopramide on muscle sympathetic nerve 1165 activity in humans., Environmental medicine: annual report of the Research Institute of Environmental Medicine Nicotine and the nicotinic cholinergic system in COVID-19 Newly discovered anti-inflammatory properties of the benzamides and nicotinamides, in: ADP-Ribosylation Reactions: From Bacterial Pathogenesis to Cancer IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 and other diseases with tissue inflammation Oxymatrine exerts 1180 organ-and tissue-protective effects by regulating inflammation, oxidative stress, apoptosis, and fibrosis: From bench to bedside The protective role of oxymatrine on neuronal cell apoptosis in the hemorrhagic 1185 rat brain Serum cytokine and chemokine profile in relation to the severity of coronavirus disease 2019 in China In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs Developed a novel drug repurposing approach integrating literature-based discovery and knowledge graph completion Constructed a biomedical knowledge graph for drug repurposing on PubMed and COVID-19 research literature Evaluated five state-of-the-art, neural knowledge graph completion methods for the task of drug repurposing Generated plausible hypotheses regarding mechanisms of proposed drugs using discovery patterns Proposed novel drugs that were not published in the literature and are not in clinicaltrials We thank François-Michel Lang, Leif Neve, and Jim Mork for their assistance with processing the CORD-19 dataset with SemRep and providing updates to SemMedDB. We acknowledge Tom Rindflesch for his encouragement with the 805 project.